BIO-TECHNE Corp vs Zoom Video Communications, Inc. — how do they compare? BIO-TECHNE Corp trades at $72.46 (market cap $11.36B), while Zoom Video Communications, Inc. trades at $94.94 (market cap $27.62B). The key difference: Zoom Video Communications, Inc. is far larger — about 2.4× BIO-TECHNE Corp's market cap, and BIO-TECHNE Corp pays a 0.44% dividend while Zoom Video Communications, Inc. pays none. Which is the better fit depends on your goals — on Pluang, investors hold BIO-TECHNE Corp for 63 Days and Zoom Video Communications, Inc. for 92 Days on average.
| TECH | ZM | |
|---|---|---|
Market Cap | $11.36B | $27.62B |
Volume | 5,390,331 | 3,913,188 |
Sector | Health | Technology |
52-Week High | $72.61 | $111.88 |
52-Week Low | $43.31 | $72.72 |
Typical Hold Time | 63 Days | 92 Days |
Enterprise Value | $11.39B | $20.43B |
Dividend Yield | 0.44% | — |
Signals from Pluang's Aura AI — not financial advice
TECH trades at $72.53, near its 52-week high of $72.70, with a bullish technical signal from moving averages. The company reported mixed quarterly earnings, beating in Q4 2025 and Q2 2026 but missing in Q1 2026. Revenue for 2025 was $1.22B, with a net income margin of 14.97%. Valuation ratios are elevated, with a P/E of 62.46 and P/S of 9.36. A significant development is the shareholder-approved acquisition by Merck KGaA at $73.00 per share, pending completion.
The outlook is heavily influenced by the pending acquisition, offering a near-term price ceiling. Fundamentals show solid profitability but high valuation multiples. Risks include acquisition deal completion uncertainty and integration challenges. Analyst sentiment is mixed with no sell ratings, but the consensus price target of $65.78 suggests limited upside from current levels, making the stock a hold pending acquisition closure.
Zoom Communications (ZM) trades at $94.77, up 0.61% today, with a bullish technical signal supported by moving averages. The company reported strong profitability with a net income margin of 65.19% and ROE of 32.14% for 2026. Recent earnings beats in Q1 and Q2 2026, alongside AI-driven product launches like the Revenue OS, highlight growth momentum. Analyst consensus is a Buy with a $118.08 price target, though mixed sentiment persists with 55.1% Hold ratings.
The outlook for ZM is positive, driven by AI integration and earnings strength, but risks include reliance on international sales and competitive pressures. Upside potential exists if the company meets Q3 2026 EPS expectations of $1.50, though volatility near resistance at $95-$97 may challenge short-term gains.
Trailing returns across standard periods
What Pluang investors did over the last 30 days
No sentiment data available yet.
Latest headlines on both assets
Based in Minnesota, Bio-Techne is a life sciences manufacturer supplying consumables and instruments for the pharma, biotech, academic, and diagnostic markets. The company reports in two segments, protein sciences (75% of revenue), and diagnostics and genomics (25%). The protein-focused segment makes equipment and associated consumables for protein characterization and analysis and sells antibodies for research and clinical purposes. In diagnostics, Bio-Techne provides controls and calibrators for diagnostic manufacturers and has a portfolio of diagnostic oncology assays. The United States accounts for about 55% of revenue, and the firm also has operations in EMEA (20% of sales), the U.K. (5%), and APAC (15%), with the rest of the world accounting for the remaining 5%.
Read more on TECH →Zoom Video Communications, Inc. develops a people-centric cloud service that transforms real-time collaboration experience. The Company offers unified meeting experience, a cloud service that provides a 3-in-1 meeting platform with HD video conferencing, mobility, and web meetings. Zoom Video Communications serves customers worldwide.
Read more on ZM →